Gottlieb Q&A: Sen. Murray Wants To Know About Generic Labeling Rule
US FDA Commissioner nominee offers master class in how to respond to congressional inquiries – and throws in some policy insight for good measure.
You may also be interested in...
Senate committee votes to send the FDA Commissioner nominee to the Senate floor, but with only two Democratic votes.
Chicago jury finds GSK failed to adequately warn about risk of suicidal behavior in patients over age 24 taking paroxetine; GSK argued that FDA had found no increased risk in this population.
US agency could reconsider requirement that instructions for use be same for branded and generic products, FDA Commissioner-nominee Scott Gottlieb suggests, while also leaving door open to statutory changes in Hatch-Waxman Act.